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Abstract Although monotherapy with angiostatic drugs is
still far from effective, there is abundant evidence that
angiostatic therapy can improve the efficacy of conven-
tional treatments like radiotherapy. This has instigated
numerous efforts to optimize and clinically implement the
combination of angiostatic drugs with radiation treatment.
The results from past and present clinical trials that
explored this combination therapy indeed show encourag-
ing results. However, current findings also show that the
combination has variable efficacy and is associated with
increased toxicity. This indicates that combining radio-
therapy with angiostatic drugs not only holds opportunities
but also provides several challenges. In the current review,
we provide an update of the most recent insights from
clinical trials that evaluated the combination of angiostatic
drugs with radiation treatment. In addition, we discuss the
outstanding questions for future studies in order to improve
the clinical benefit of combining angiostatic therapy with
radiation therapy.
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Introduction
In 2004, more than 30 years after the proposition that
targeting the vascularization of malignant tissues might
provide a therapeutic benefit [1], the first angiostatic drug
was approved by the FDA, i.e., bevacizumab (Avastin)
[2]. Currently, bevacizumab, a monoclonal antibody tar-
geting the vascular endothelial growth factor (VEGF), is
FDA approved for the treatment of metastatic colorectal
cancer (mCRC), metastatic renal cell cancer (mRCC), non-
small cell lung cancer (NSCLC) and glioblastoma, while its
treatment efficacy in other malignancies is still being
investigated. In addition, in the last decade the FDA has
approved several other angiostatic drugs for the treatment
of different malignancies (Table 1). Despite the increasing
number of angiostatic drugs targeting different angiogenic
pathways [3–5], thus far only limited clinical benefit of
angiostatic therapy has been demonstrated. For example,
bevacizumab monotherapy in patients with previously
treated mCRC resulted in an inferior overall survival (OS)
of 10.2 months compared to a OS of 10.8 months with
standard chemotherapy (FOLFOX4) [6], whereas the first-
line therapy with sorafenib in patients with mRCC results
in a similar progression-free survival as treatment with
interferon alpha-2a [7]. A well-known exception to this is
sunitinib which has been shown to improve OS in the first-
line treatment of patients with metastatic RCC as compared
to interferon alpha [8, 9].
Despite their limited benefit as monotherapeutics, both
clinical and preclinical studies have shown that angiostatic
drugs can improve the treatment efficacy when combined
with other treatments, including chemotherapy [10–14],
photodynamic therapy [15–17], immunotherapy [18, 19],
miRNA-based therapy [4] and radiotherapy [13, 20–23].
Regarding the latter, promising preclinical observations
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instigated numerous clinical trials exploring the benefit of
combining angiostatic drugs with radiotherapy. Five years
ago, we evaluated the clinical opportunities and challenges
that accompany the combination of radiotherapy with
angiostatic therapy [24]. At that time, over 75 trials were
still ongoing. Here, we present an updated overview of the
outcome of these clinical trials. In addition, we evaluate the
novel insights from these studies and discuss the out-
standing questions that new trials should answer in order to
improve the clinical benefit of combining radiotherapy
with angiostatic treatment.
The rationale behind combining angiostatic drugs
with radiotherapy
At the first sight, the rationale to combine radiotherapy
with angiostatic drugs appears counterintuitive since the
effect of radiotherapy relies on the presence of oxygen [25]
while angiostatic drugs aim to block tumor oxygenation.
Despite this apparent conflict, several preclinical studies
have shown that angiostatic treatment can enhance tumor
oxygenation, thereby increasing the efficacy of radiation
treatment [13, 22, 26–28]. The mechanisms by which
angiostatic drugs improve tumor oxygenation are still not
fully understood. Initially, it was hypothesized that selec-
tive killing of the endothelial cells would reduce their
oxygen consumption and increase vascular permeability.
This would result in an increased oxygen availability and
diffusion into the tumor tissue [29, 30]. Later studies
indicated that angiostatic treatment might improve tumor
oxygenation by remodeling of the abnormal and dysfunc-
tional tumor vasculature to a more normal and functional
phenotype [27, 31]. This ‘vascular normalization’ is
hypothesized to result from restoring the balance between
pro- and anti-angiogenic signals. It results in more
stable vessels, lower interstitial fluid pressure, better per-
fusion and consequently a better overall tumor oxygenation
[22, 32–34]. For example, our previous work has focussed
on the role of galectins in tumor angiogenesis and cancer
[35–40]. This was instigated by our discovery of galectin-1
as a pro-angiogenic factor that is essential for endothelial
Table 1 FDA-approved angiostatic drugs for cancer treatment
Drug (trade name) Main target(s) Cancer typea
Antibodies
Aflibercept (Zaltrap) VEGF/PlGF mCRC
Bevacizumab (Avastin) VEGF mCRC, NSCLC, mRCC, Glioblastoma
Ramucirumab
(Cyramza)
VEGFR2 Advanced stomach cancer or gastroesophageal junction adenocarcinoma
Panitumumab
(Vectibix)
EGFR mCRC (wt KRAS)
Cetuximab (Erbitux)b EGFR mCRC (wtKRAS), metastatic non-small cell lung cancer and head and neck
cancer
Small molecules
Axitinib (Inlyta) VEGF-R1/2/3, PDGFR, c-KIT RCC
Everolimus (Afinitor) FKBP12/mTORC1 RCC, breast cancer, NET
Erlotinib (Tarceva) EGFR NSCLC, PC
Pazopanib (Votrient) VEGFR-1/2/3, PDGFR-a/b, c-Kit RCC, STS
Regorafenib (Stivarga) VEGFR-2, TIE-2 mCRC, GIST
Sorafenib (Nexavar) C-RAF, B-RAF, VEGFR-2/3,
PDGFR-b,
RCC, HCC, thyroid cancer
Sunitinib (Sutent) VEGFR-1/2/3, PDGFR-a/b, c-Kit mRCC, imatinib-resistant GIST, progressive NET in the pancreas
Thalidomide
(Thalomid)
Cereblon, unknown Multiple myeloma
Vandetanib (Caprelsa) VEGFR-1/2/3, EGFR, RET Medullary thyroid cancer
Cabozantinib
(Cabometyx)
VEGF-R2, c-MET Advanced RCC, medullary thyroid cancer
Lenvatinib (Lenvima) VEGF-R1/2/3 Advanced RCC, thyroid cancer
a m metastatic, CRC colorectal cancer, NSCLC non-small cell lung cancer, RCC renal cell cancer, PC pancreatic cancer, NET neuroendocrine
tumors, STS soft tissue sarcoma, HCC liver cancer, GIST gastrointestinal cancer
b Was also approved by the FDA in 2004 for the treatment of mCRC [2]
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cell function during tumor angiogenesis [41–44]. Impor-
tantly, we identified galectin-1 as the endothelial cell target
of a synthetic angiostatic peptide named anginex [41, 45].
Treatment of murine tumor models with anginex (or
bevacizumab) was shown to improve tumor oxygenation
and consequently to enhance the anti-tumor effect of
radiotherapy [22]. This is in line with other preclinical
studies which have linked vascular normalization to an
enhanced efficacy of radiation treatment [13, 27]. At the
same time, it has been shown that the vascular normal-
ization occurs only transiently and that continuation of
angiostatic treatment eventually causes vessel regression
and reduced tumor oxygenation [22, 31, 34]. Hence, ade-
quate scheduling is important to ensure that radiation is
applied during the normalization window [22]. In addition,
to what extent vascular normalization occurs in the clinical
setting and whether or not it contributes to better tumor
oxygenation is still under debate [46, 47]. While the latter
still requires further investigation, the potential effects on
tumor oxygenation certainly provide a rationale to combine
angiostatic drugs with radiotherapy.
Another rationale to combine angiostatic therapy with
radiotherapy is the observation that tumor irradiation can
directly affect tumor vascularization, perfusion and oxy-
genation. Such radiation-induced vascular changes appear
to be dependent on the dose-scheduling regime. Based on a
literature study, different dose-dependent effects of radio-
therapy on the vasculature could be distinguished, i.e.,
vessel deterioration, vessel preservation and vessel induc-
tion [48]. The latter, i.e., the stimulation of tumor vascu-
larization and perfusion, is predominantly observed during
fractionated (low-dose) radiotherapy. For example, Mayr
et al. [49] used contrast enhanced MRI to determine tumor
perfusion in cervical cancer patients receiving fractionated
radiotherapy (±5 9 2 Gy/week for 4–5 weeks). They
observed increased perfusion after 2 weeks of treatment
after which a decline in perfusion was observed. A com-
parable finding was reported by Shibuya et al. [50] using
perfusion CT. Improved tumor perfusion following frac-
tionated irradiation was also reported in other tumor types,
including in non-locally advanced rectal tumors (5 9 5 Gy)
[51], and inoperable non-small cell lung tumors
(6 9 4.5 Gy) [52]. In the latter study, the increase in tumor
blood volume occurred both at the rim and the center of the
tumor albeit to a lesser extent in the tumor center [52]. We
also observed improved perfusion in the center of xenograft
colorectal tumors in mice that received 3 weeks of frac-
tionated irradiation (5 9 2 Gy/week) [28]. Interestingly, the
observation that fractionated irradiation can induce tumor
tissue perfusion is in line with reports that fractionated
radiotherapy can improve tumor oxygenation [53, 54].
Thus, improved tumor perfusion might represent an addi-
tional mechanism of radiotherapy-induced tumor
oxygenation, next to previously described mechanisms like
decreased oxygen consumption, increased inflammation and
reduced tumor volume [55]. While the improved perfusion
and oxygenation might increase the efficacy of subsequent
irradiations, our recent findings confirm that the tumor areas
with increased perfusion also contained more viable tumor
tissue [28]. Apparently, the improved tumor vascularization
and oxygenation can also contribute to tumor cell survival
or to tumor regrowth following fractionated radiotherapy.
Thus, blocking this effect by angiostatic drugs could
improve the efficacy of the radiation treatment.
Altogether, the addition of angiostatic drugs to radio-
therapy might be effective by (1) transiently improving
tumor oxygenation and/or (2) counteracting radiotherapy-
induced tumor (re)vascularization to prevent or delay
tumor recurrence. However, it is evident that optimal dose-
scheduling of both treatment modalities is the key to
achieve beneficial effects of the combination therapy. After
all, dose-scheduling of angiostatic drugs will influence
whether and when vessel normalization occurs, thereby
affecting the efficacy of radiotherapy. At the same time,
dose-scheduling of radiotherapy will influence tumor per-
fusion and oxygenation, thereby affecting the efficacy of
angiostatic drugs. All this has been recognized and studied
by us and others in different preclinical tumor models
[22, 23, 56, 57]. The current challenge is to translate all
these insights into clinically applicable protocols. For this,
several outstanding questions have to be answered, espe-
cially with regard to dose-scheduling and with regard to the
commonality of the observed effects of radiotherapy on
tumor vascularization and perfusion. Insights from past,
present and future clinical trials on the efficacy of the
combination therapy can help to answer these questions.
The past results of combined angiostatic/radiation
therapy
In 2012, we performed an extensive review of the results of
clinical trials that combined radiotherapy with angiostatic
treatment. The overall conclusion at that time was that this
combination treatment generally results in favorable out-
comes with regard to tumor response and patients survival
[24]. The observed efficacy appeared to depend not only on
the type of drug and the type of tumor but also on the
proper scheduling and dosing of both therapies which was
in line with preclinical observations. In fact, exploring the
optimization of dose-scheduling was identified as an
important future challenge, especially since concerns were
raised regarding the increased toxicity that is observed in
patients who received the combination treatment
[24, 58, 59]. Interestingly, our recent studies in preclinical
tumor models indeed show that optimizing the treatment
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schedule does allow dose reductions without loss of treat-
ment efficacy, i.e., decrease in tumor volume [23, 28]. This
is in line with a previously published mouse study [60] as
well as with several clinical case reports [61, 62]. However,
strong clinical evidence that dose reduction does result in
lower toxicity while not affecting the efficacy of the
combination treatment is still lacking.
Collectively, past clinical trials confirmed the preclinical
findings that the combination of angiostatic drugs with
tumor irradiation could provide opportunities to improve
patient outcome. However, the combination therapy was
found to be associated with increased toxicity profiles
which pointed toward the need to improve dose-
scheduling.
The present progress in combined angiostatic/
radiation therapy
The 2012 paper by Kleibeuker et al. listed 78 ongoing
clinical trials combining angiostatic drugs with radiother-
apy [24] which was illustrative of the expectations
regarding the clinical benefit of this combination treatment
strategy. At present, 45 of these trials have been completed
and 19 trials are still ongoing. In addition, four have been
terminated due to either an insufficient number of partici-
pants, unacceptable toxicity or withdrawal of support from
the sponsor, whereas the remaining studies did not have a
recent status update (Table 2). Out of the 45 completed
trials, 22 published study results in PubMed-indexed
journals. Of note, the majority of these published trials, i.e.,
18, evaluated the combination of (chemo)radiotherapy with
bevacizumab (Table 3). Since we recently discussed the
opportunities of combining radiotherapy with another
widely used angiogenesis inhibitor, i.e., sunitinib [63], we
will focus here mainly on bevacizumab.
Combining bevacizumab with (chemo)radiotherapy
In 2014, Gilbert et al. and Chinot et al. published the results
of two phase III trials that evaluated whether bevacizumab
improves the efficacy of standard chemoradiotherapy for
patients with newly diagnosed glioblastoma [64, 65]. Both
studies were initiated based on previous observations in
phase I/II trials that suggested a potential benefit of this
combination treatment [66–69]. In the trial of Gilbert et al.,
bevacizumab (or placebo) was added in the fourth treat-
ment week of concurrent radiotherapy (30 9 2 Gy) plus
temozolomide, whereas Chinot et al. started bevacizumab
(or placebo) already in the first treatment week of radio-
therapy (30 9 2 Gy) plus temozolomide. Gilbert et al.
found no benefit of bevacizumab in terms of overall sur-
vival (OS; 15.7 vs. 16.1 months; HR 1.13) and
progression-free survival (PFS; 10.7 vs. 7.3 months; HR
0.79), but reported a worse quality of life and a decline in
neurocognitive function in the bevacizumab group. Patients
treated with bevacizumab experienced grade 3 or higher
adverse events more frequently [65]. Chinot et al. did
observe a prolonged PFS in the bevacizumab group as
compared to placebo (10.6 vs. 6.2 months), but also failed
to show a significant difference in OS. Again, grade 3 or
higher adverse events were more common in the beva-
cizumab cohort (66.8 vs. 51.3% in the placebo group) [64].
Of note, since the statistical design of the two trials was not
comparable, a direct comparison cannot be made. How-
ever, both studies point toward a favorable PFS with the
addition of bevacizumab to radiotherapy plus temozolo-
mide in newly diagnosed glioblastoma, especially when
combination treatment is initiated at the start of radio-
therapy. Unfortunately, the favorable PFS is accompanied
with increased toxicity. Thus, it remains to be seen if
bevacizumab is really a beneficial addition to the first-line
treatment in glioblastoma patients.
Overall, the clinical value of combining bevacizumab
with radiotherapy is open for debate, especially since most
current trials either report no clinical benefit [70–76] or
only a (minor) benefit in PFS or pCR (pathological com-
plete response) [77, 78]. For example, several phase II
studies have been performed in rectal cancer patients based
on promising results in phase I trials [79, 80]. Borg et al.
[71] added bevacizumab to neoadjuvant 5-FU and RT for
46 patients with stage III rectal cancer before total
mesorectal excision, evaluating the proportion of patients
achieving a pathological complete response (pCR;
ypT0N0). The study did not reach a significant difference
from expected pCR (10.0%) with a rate of 11.4%. Salazar
et al. also failed to show a significant difference in pCR
with the addition of bevacizumab to capecitabine-based
neoadjuvant chemoradiotherapy (CRT) in 44 patients with
stage II/III rectal cancer as compared to 46 patients
undergoing only CRT (16 vs. 11%, p = 0.54) [75]. Com-
parable observations were reported by Dellas et al. [81].
More recently, Landry et al. reported on the 5-year clinical
outcomes of a phase II trial in patients with locally
advanced rectal cancer that received preoperative
chemoradiation with bevacizumab followed by postopera-
tive chemotherapy (FOLFOX) plus bevacizumab. Despite
excellent 5-year OS and DFS, the primary endpoint (30%
pCR) was not reached. Moreover, the treatment schedule
was associated with substantial neoadjuvant and surgical
toxicity. This resulted in low compliance to adjuvant
treatment, and therefore, it was recommended to not further
explore this combination treatment [73]. Also Kennecke
et al. [82], who evaluated preoperative bevacizumab
treatment added to oxaliplatin, capecitabine and radiation


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































suggested that the results of their study did not justify a
phase III trial aimed at exploring the benefit of neoadjuvant
bevacizumab in rectal cancer. Of note, Spigel et al. [83]
observed an improved pCR rate of 29% in patients with
stage II/III rectal cancer who were treated prior to surgery
with 5-fluorouracil, bevacizumab and radiotherapy. Also
Xiao et al. [84] reported that sandwich-like neoadjuvant
therapy with bevacizumab was safe and effective for
locally advanced rectal cancer. Possibly, differences in the
timing of surgery, i.e., 2–8 versus 6–8 weeks following
chemoradiation could underlie the different observations
[85]. This should be taken into account when further
optimizing dose-scheduling of both treatments in rectal
cancer. Regarding scheduling, the patient accrual in a
single-arm phase II study by Resch et al. [86] in rectal
cancer patients that received bevacizumab concurrent with
chemoradiation was terminated due to toxicity. Based on
these current results, it can be argued whether the combi-
nation of radiotherapy with bevacizumab will provide a
clinical benefit to rectal cancer patients.
A similar conclusion can be claimed regarding the com-
bination of radiotherapy and bevacizumab in nasopharyn-
geal cancer. In a phase II clinical trial by Lee et al. [74], 44
patients with stage IIB–IVB nasopharyngeal cancer
received radiotherapy (33 9 1.2 Gy) in combination with
three cycles of bevacizumab and cisplatin, followed by
standard adjuvant treatment consisting of fluorouracil in
combination with bevacizumab. While the study was
designed to test toxicity, the estimated PFS was lower than
previously reported in standard therapy (75 vs. 86%). The
estimated PFSwas also not reached in the study by Yao et al.
in patients with locally advanced squamous cell carcinoma
of the head and neck that received bevacizumab concurrent
with chemoradiation followed bymaintenance bevacizumab
treatment. Nevertheless, they concluded that the regimen
could be further studied in appropriately selected patients,
especially those not eligible for cisplatin administration
[76]. Of note, a study combining both bevacizumab and
erlotinib with concurrent chemoradiation in head and neck
cancer patients appeared to give favorable locoregional
control and OS compared to historical controls. It was sug-
gested to further study this in a randomized study [87].
Altogether, most current studies combining beva-
cizumab with radiotherapy only show moderate to no
clinical benefit at all. In addition, in most studies the
combination treatment is associated with increased albeit
manageable toxicities. All this is in line with previous
observations [24].
Combining sorafenib with (chemo)radiotherapy
As mentioned previously, most trials on combining angio-
static drugs with irradiation that were published between
2012 and 2015 involved the addition of bevacizumab to
radiotherapy. However, a few trials assessed the combina-
tion with other angiostatic drugs. For example, several
studies evaluated the addition of the tyrosine kinase inhibitor
sorafenib to radiation therapy. Brade et al. [88] tested the
safety of combining sorafenib with SBRT (up to 51 Gy) in
liver cancer patients. They observed a high rate of adverse
events and DLTs, predominantly in patients in which a high
volume of liver was irradiated. This is in line with reports
from Goody et al. and Dawson et al. [89, 90]. Based on these
observations, it appears not advisable to combine concurrent
sorafenib with SBRT in patients with locally advanced HCC
[88]. Interestingly, Chen et al. [91] observed more accept-
able toxicities when combining concurrent sorafenib with
conventional fractionated radiotherapy (2.0–2.5 Gy/fraction
up to 60 Gy). Since the response rate appeared similar
compared to historical studies of radiotherapy alone, it was
concluded that the schedule could be further investigated,
albeit with caution [91]. A comparable conclusion was
drawn by Hainsworth et al. [92] who applied maintenance
sorafenib plus temozolomide treatment following fraction-
ated radiotherapy (30 9 2 Gy) plus temozolomide in newly
diagnosed glioblastoma patients. Of note, the necessity to
combine radiotherapy with sorafenib with caution was fur-
ther exemplified by the observation that sorafenib prior to
radiotherapy can result in reduced liver volumes which
might require adjustment of the radiation dose [93]. In
addition, sorafenib treatment was associated with gastroin-
testinal perforation after radiotherapy in advanced renal cell
carcinoma patients [94]. These findings again illustrate the
necessity to gain more insight in the effects of alternative
dose-scheduling regimes when combining radiotherapy with
angiostatic drugs.
Combining sunitinib with (chemo)radiotherapy
The opportunities and challenges of this combination
treatment were previously reviewed by Kleibeuker et al.
[63]. Here, we briefly discuss some of the latest insights.
Recently, Jakob et al. published the results of two phase I
trials that explored the feasibility of concurrent sunitinib
and radiotherapy for treatment of locally advanced soft
tissue sarcoma (STS) prior to surgery [95, 96]. They
observed acceptable toxicity which was comparable to
other studies that evaluated the combination of radiother-
apy with angiostatic drugs in STS, including pazopanib
[97] and bevacizumab [98]. Based on favorable responses,
all these studies recommended further investigation of the
combination treatment in future trials [95–98]. However, a
single phase Ib/II study of sunitinib with radiotherapy in
soft tissue sarcoma reported unacceptable toxicities as well
as increased local relapse rates [99]. Interestingly, the ini-
tial dose of sunitinib used in this study was higher
Angiogenesis
123
compared to the other studies (50 vs. 25–37.5 mg), which
might explain the observed increased toxicity. Horgan et al.
explored the feasibility, tolerability and efficacy of suni-
tinib adjuvant to surgery in locally advanced esophageal
cancer patients that received neoadjuvant chemoradiation
(irinotecan/cisplatin ? 25 9 2 Gy). This regime appeared
feasible although it was poorly tolerated. In addition, the
treatment did not show any clinical benefit compared to
(historical) controls [100]. All these findings support the
previous conclusions by Kleibeuker et al. [63] that effec-
tive combination of radiotherapy with sunitinib relies on
better insights in the optimal dosing and scheduling of the
combination treatment.
Combining other angiostatic drugs
with (chemo)radiotherapy
Besides the trials discussed above, a handful of studies
described the combination of additional angiostatic drugs
with radiotherapy. For some of these, e.g., SU5416 (se-
maxanib) and vandetanib, no trial results have been pub-
lished, possibly because the combination treatment is no
longer of interest. For other inhibitors, some information is
available. As mentioned above, pazopanib was combined
with radiotherapy in soft tissue sarcoma patients [97].
Based on a dose–escalation study, Haas et al. [97] con-
cluded that neoadjuvant pazopanib (daily dose of 800 mg
daily for 6 weeks) in combination with 50 Gy (25 9 2 Gy)
appeared safe, albeit that toxicity should be carefully
monitored in future studies. Of note, a case study reported
complete remission of gastric and esophageal metastases in
a renal cancer patient after treatment with radiotherapy
(10 9 3 Gy) and neoadjuvant as well as adjuvant pazo-
panib [101]. The study by Haas et al. also reported favor-
able responses which warrants further studies on the
clinical benefit of radiotherapy combined with pazopanib.
Two recent studies evaluated the combination of endo-
star/endostatin with radiotherapy in NSCLC patients. In the
study by Bao et al. [102], patients with unresectable stage III
NSCLC were treated with endostar combined with concur-
rent chemoradiation (docetaxel/cisplatin ? 30–33 9 2 Gy).
They reported promising short-term efficacy and local con-
trol rates, and the treatment regimen was generally well
tolerated [102]. These findings are in agreement with a
previous study in NSCLC patients and warrant future eval-
uation of this treatment [103]. On the other hand, Sun et al.
evaluated the addition of endostatin to concurrent
chemoradiation (carboplatin/paclitaxel ? 30–33 9 2 Gy)
followed by maintenance chemotherapy ? endostatin in
patients with unresectable stage III NSCLC. This study was
closed early because of unacceptable toxicity, i.e., four out
of ten patients presented with grade III pulmonary toxicity
[104].
Collectively, the results of the current studies that
evaluate the feasibility to combine angiostatic drugs with
radiotherapy have not provided remarkable novel insights
regarding this treatment regimen. The occurrence of toxi-
cities remains an issue of concern [105]. Combining
radiotherapy with bevacizumab generally shows limited
efficacy while the combination with other angiostatic drugs
has shown favorable responses, but still awaits further
confirmation in (randomized) clinical studies. Optimization
of dosing and scheduling of both treatment modalities
remains one of the key future challenges.
The future of combined angiostatic/radiation
therapy
Based on preclinical studies as well as on different clinical
observations, it still appears feasible that the combination of
angiostatic drugs with radiotherapy can be a valuable addi-
tion to current therapeutic strategies for cancer patients. At
the same time, the insights from past and present clinical
trials have made it clear that successful clinical implemen-
tation of this combination treatment requires considerable
investigations. As evident from our current and previous
review, there are a large number of studies ongoing that will
help to resolve some of the outstanding questions, especially
with regard to feasibility and toxicity of combining different
angiostatic drugs with different radiation regimes in a broad
spectrum of cancer types. Moreover, several novel trials
have been initiated in the past 5 years, for example with
bevacizumab (Table 4). The results of all these trials will
help to make the necessary steps to bring effective combi-
nation therapy to cancer patients.
One of the most urgent issues to address involves the
optimal dose-scheduling of both treatment modalities, not
only to improve treatment efficacy, but also because the
results from past studies indicated that inadequate dose-
scheduling can induce severe toxicities [24, 63]. With
regard to dosing, it is important to explore how alterations
in dosing of either treatment affect the toxicity and efficacy
of combination therapy. For example, Carlson et al. and
Omura et al. explored the addition of bevacizumab to
hypofractionated radiotherapy in newly diagnosed
glioblastoma patients [106, 107]. In the latter study,
patients received hypofractionated stereotactic radiother-
apy (6 9 6 ? 4 Gy over 2 weeks) with concurrent and
adjuvant temozolomide plus bevacizumab. The regime was
identified as safe and was found to have a comparable
effect on OS as compared to historical standard treatment.
Moreover, the reduced treatment period appears more
convenient for cancer patients [106]. The study by Carlson
et al. [107] also reported that the addition of concurrent/
adjuvant bevacizumab to hyperfractionated IMRT
Angiogenesis
123
(10 9 6 Gy) did not improve OS while a somewhat higher
rate of grade 3 toxicity was observed. Nevertheless, these
studies provide the first evidence that altered dose-
scheduling can be explored in order to improve treatment
efficacy. In this light, our recent preclinical results are also
of interest. We observed that concurrent combination
treatment allowed a 50% reduction in dosing of the
angiostatic drug sunitinib without affecting the therapeutic
efficacy of conventional fractionated radiotherapy [23, 28].
Of note, the low dose was also effective in combination
with single high-dose irradiation. These observations could
provide opportunities to improve combination treatment
both in the curative and in the palliative setting. However,
the applicability of such approaches in a clinical setting
still awaits confirmation.
Apart from dosing, the scheduling of both treatments is
also of importance. Different effects have been observed
between concurrent and (neo)adjuvant combination of
angiostatic drugs with radiotherapy [24, 63]. Recently,
Avallone et al. [108] reported on differential clinical
effects of combining bevacizumab with chemoradiation
either concomitantly or sequentially in high-risk locally
advanced rectal cancer patients. While the endpoint was
reached using the sequential schedule, the concomitant
Table 3 Overview of trials combining RTx with bevacizumab published between 2012 and 2017





NCT01332929 I Brain metastases Neo/conc 15 9 2 or




NCT00805961 II GBM (first-line
treatment)
Conc/adj 30 9 2 Gy Temozolomide/everolimus Yes (PFS)b [77]
NCT01186406 II GBM (ND) Conc/adj 30 9 2 Gy Temozolomide No (OS
and PFS)
[65]









Conc 45 Gy in 25
fractions
Yes (PFS) [78]
NCT00281840 II HNSCC (stage III/
IV)
Conc/adj 40 9 1.8 Gy Docetaxel No (PFS)b [76]
NCT00408694 II NPC (stage IIB–
VB)
Conc/adj 33 9 2.12 Gy Cisplatin/5-FU No (PFS)b [74]
NCT00460174 II Pancreatic cancer
(localized)
Neo 15 9 2.4 Gy Gemcitabine NAc [110]
NCT00321685 II RC (LA non-
metastatic)
Conc 28 9 1.8 Gy Capecitabine/oxaliplatin
(FOLFOX)
No (pCR)b [73, 115]
NCT00865189 II RC (LA) Neo/conc 25 9 1.8 Gy FOLFOX/5-FU No (pCR)b [71]
NCT01043484 II RC (localized) Conc 25 9 1.8 Gy Capecitabine No (pCR) [75]
NCT00308516 II RC (stage II/III) Conc/adj 28 9 1.8 Gy FU (conc)/FOLFOX6 (adj) Yes (pCR;
DFS)b
[83]
NCT00307736 I/II RC (LA) Conc 28 9 1.8 Gy 5-FU/erlotinib Yes (pCR)b [113]
NCT00308529 II SCLC (LA) Neo/conc/
adj
34 9 1.8 Gy Irinotecan/carboplatin NAd [111]
NCT00393068 II EC (operable) Conc 25 9 1.8 Gy 5-FU/paclitaxel/carboplatin/
erlotinib
No (pCR) [70]
NCT00140556 I HNSCC/NPC Conc 70 Gy in twice
daily 1.25 Gy
Cisplatin/erlotinib Yes (OS)b [87]
NCT00392704 II HNSCC (LA) Neo/conc 38 9 1.8 Gy Paclitaxel/carboplatin/5-FU (neo);
Paclitaxel/erlotinib (conc)
Yes (PFS)b [112]
a Responders according RECIST in patients treated with increasing dose bevacizumab
b Compared to historical studies, NA not assessed
c Study was set up to compare different response measures
d Due to early trial closure related to toxicity
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schedule arm was terminated early because of inconsistent
activity. Also, toxicity and postoperative complications
appeared to be higher after concomitant treatment [108].
This is illustrative of the importance of optimal scheduling,
and it is therefore essential that the effect of scheduling is
further explored in future studies.
Finally, future studies should aim to integrate insights
on tumor perfusion with the observed response to therapy.
As described above, the main rationales to combine
angiostatic drugs with radiotherapy are (1) to improve
tumor perfusion and oxygenation by vessel normalization
and (2) to counteract radiation-induced tumor (re)vascu-
larization. Both aims require different approaches with
regard to dose-scheduling. Thus, it is vital in obtain
information of tumor perfusion and oxygenation prior to
treatment planning but also to monitor changes in these
parameters during treatment. This could improve treatment
efficacy. Several of the trials that were discussed here also
included perfusion measurements or explored (bio)markers
that could predict response to therapy. However, it is out-
side the scope of the current review to discuss the insights
of these studies regarding these issues. It suffices to state
that the development and implementation of noninvasive
imaging techniques to measure perfusion and early tumor
responses are important to better explain and/or predict the
response to the combination of angiostatic drugs with
radiotherapy.
Conclusions
Despite the limited clinical efficacy of angiostatic drugs as
monotherapeutics, there is ample evidence that angiostatic
therapy can be valuable when combined with other treat-
ment modalities, including radiotherapy. This involves the
beneficial effects of angiostatic drugs on tumor perfusion
prior to and during radiation as well as their inhibitory
effects on tumor (re)vascularization during or after radia-
tion. Past and present clinical trials that combined angio-
static drugs with radiotherapy indeed showed that this
approach can improve therapeutic outcome. However, this
is mainly observed in phase I/II trials and actual validation
of clinical benefit awaits confirmation in larger randomized
phase III trials. Moreover, variable efficacy as well as
increased toxicity has been reported when angiostatic drugs
are combined with radiotherapy. This is most likely due to
non-optimal dosing and inadequate scheduling of both
treatment regimes. Thus, exploring the close relation
between dose-scheduling represents the key challenge for
future research regarding combination treatment. This
Table 4 Newly initiated trials combining bevacizumab with radiotherapy (2012–2017)
Trial Phase Diseasea Schedulingb Radiotherapy regimec Chemotherapy Statusd
NCT01730950 II GBM Conc IMRT, 3D-CRT, or proton beam RT 5 days a week
for 2 weeks
None 2
NCT01746238 I STS Conc 6 weeks, 5 days a week Doxorubicin 3
NCT02313272 I GBM Conc Hypofractionated SRT Pembrolizumab 3
NCT01871363 II RC Conc 25 9 2 Gy Capecitabine 5
NCT01743950 II GBM Conc 27 9 2 Gy (PRDR) None 3
NCT01569984 II mCRC Neo Up to 60 Gy in six fractions, alternating weekdays for
2 weeks
None 1
NCT02185352 II BM in
BC
Neo WBRT Etoposide, cisplatin 3
NCT01580969 Ib/II Glioma Conc Individually determined Minocycline 3
NCT01588431 II HNSCC Neo/conc 5 weeks, 70 Gy Docetaxel, cetuximab,
cisplatin
2
NCT01818973 II RC Neo/conc 5 weeks, 50 Gy Capecitabine ? oxaliplatin 3
NCT01554059 II RC Neo/conc 5 weeks, 50 Gy 5-FU, oxaliplatin 1
NCT02812641 II EC Conc 4 weeks, 40 Gy Cisplatin, 5-FU 3
NCT02672995 I BM Conc Three fractions, 18–27 Gy None 3
a Disease: GBM glioblastoma, STS soft tissue sarcoma, RC rectal cancer, mCRC metastatic colorectal cancer, BM brain metastasis, BC breast
cancer, HNSCC head and neck squamous cell cancer, EC esophageal cancer
b Scheduling: scheduling of angiostatic drug to radiotherapy neo neoadjuvant, conc concurrent, adj adjuvant
c Radiotherapy: radiation is applied at a frequency of 5 days/week unless indicated otherwise. When the dose applied is unknown, this is
indicated with 9 Gy
d Status: 1 = completed; 2 = active, not recruiting; 3 = recruiting; 4 = terminated/withdrawn; 5 = unknown
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directly relates to the development of rapid and noninva-
sive imaging strategies in order to measure tumor perfusion
prior, during and after treatment. This will help to optimize
current approaches to improve treatment strategies and to
make effective combination therapy available for cancer
patients in daily clinical practice.
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